We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
CONSTELLA (Allergan Australia Pty Ltd)
Product name
CONSTELLA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
245 working days (255)
Active ingredients
linaclotide
Registration type
NCE/NBE
Indication
CONSTELLA (hard capsules) is indicated in adults for the treatment of:
- irritable bowel syndrome with constipation (IBS-C) and
- chronic idiopathic constipation (CIC) when dietary fibre, laxatives and stool softeners have not been sufficient and with adequate constipation minimisation dietary support.